<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<ibecs-document>
<record>
<header>
<identifier>ibc-62290</identifier>
<setSpec>0034-9356</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:description xml:lang="en">OBJECTIVE: To assess the utility of propofol and succinylcholine in obtaining optimal convulsions and assuring patient safety during electroconvulsive therapy. PATIENTSANDMETHODS: This was a prospective observational study of patients undergoing electroconvulsive therapy under general anesthesia with propofol and succinylcholine. We recorded patient characteristics, doses of propofol and succinylcholine, electroencephalographically-recorded duration of convulsions, and complications. Descriptive statistics were compiled and the data were subjected to analysis of correlations, comparison with the Student t test for independent samples, the Mann-Whitney U test, and analysis of variance. RESULTS: We studied 108 patients, 62% women and 38% men, 80% classified as ASA 1 and 20% as ASA 2. The patients underwent 844 sessions of electroconvulsive therapy ;their mean (SD) age was 39.95 (18.09) years. The doses of propofol and succinylcholine were 1.34 (0.32) mg·kg&#150;1 and 1.35 (0.26) mg·kg&#150;1, respectively. The mean recorded duration of the first convulsion (29.87 [22.42] seconds) was negatively correlated with age (r = &#150;0.12) and unrelated to propofol dose (r = 0.06) or body weight (r = 0.02). Male and schizophrenic patients had longer-lasting convulsions (P &lt; .01). Cardiovascular complications occurred in 2.4% and psychomotor agitation in 1.4%; there were no respiratory complications, musculoskeletal injuries, nausea, or vomiting. CONCLUSIONS: Electroconvulsive therapy can be safely applied in an operating room or similar space under general anesthesia and with a neuromuscular blockade in order to prevent psychological or musculoskeletal trauma. Propofol did not affect the convulsions at the dosages administered (AU)</dc:description>
<dc:creator>Léniz, P</dc:creator>
<dc:creator>Rioseco, A</dc:creator>
<dc:creator>Cortínez, L. I</dc:creator>
<dc:creator>Cuadra, J. C de la</dc:creator>
<dc:creator>González, A. G</dc:creator>
<dc:creator>Carrasco, E</dc:creator>
<dc:language>es</dc:language>
<dc:description xml:lang="es">OBJETIVO: Valoramos el efecto de la anestesia con propofoly succinilcolina (Sch) en obtener convulsiones óptimasy mantener la seguridad del paciente durante laterapia electroconvulsiva (TEC).PACIENTES Y MÉTODOS: Realizamos un estudio prospectivoobservacional en pacientes sometidos a TECbajo anestesia general con propofol y Sch. Registramosvariables demográficas, dosis de propofol y Sch, númerode estímulos aplicados, duración electroencefalográfica(EEG) de las convulsiones y complicaciones. Utilizamosestadísticas descriptivas, análisis de correlación, t de studentpara muestras independientes, ANOVA de una víay Mann-Whitney.RESULTADOS: Estudiamos 108 pacientes, 62% mujeresy 38% hombres, 80% ASA I y 20% ASA II, sometidos a844 sesiones de TEC, con una edad de 39,95 ± 18,09años. Las dosis de propofol y Sch fueron 1,34 ± 0,32 mgkg-1 y 1,35 ± 0,26 mg kg-1, respectivamente. La duraciónEEG de la primera convulsión (29,87 ± 22,42 segundos)tuvo una correlación negativa con la edad (r = -0,12), notuvo correlación con la dosis de propofol (r = 0,06) ni conel peso corporal (r = 0,02). Los pacientes hombres y losportadores de esquizofrenia tuvieron convulsiones demayor duración (p &lt; 0,01). Hubo complicaciones cardiovasculares(2,4%) y agitación psicomotora (1,4%); nohubo complicaciones respiratorias, ni traumatismosmusculoesqueléticos, ni náuseas ni vómitos.CONCLUSIONES: La TEC es un procedimiento segurorealizado en el quirófano o en un área similar, con anestesiageneral y bloqueo neuromuscular para prevenir eltrauma psicológico y musculoesquelético. A las dosisadministradas el propofol no afectó las convulsiones (AU)</dc:description>
<dc:source>Rev Esp Anestesiol Reanim;54(7): 414-420, ago.-sept. 2007. ilus, tab</dc:source>
<dc:identifier>ibc-62290</dc:identifier>
<dc:subject>^d29611</dc:subject>
<dc:subject>^d33110^s22045</dc:subject>
<dc:subject>^d4637^s22045</dc:subject>
<dc:subject>^d24841^s22079</dc:subject>
<dc:subject>^d8771^s22067</dc:subject>
<dc:subject>^d13776^s22079</dc:subject>
<dc:subject>^d28607</dc:subject>
<dc:subject>^d21034</dc:subject>
<dc:subject>^d771^s22074</dc:subject>
<dc:type>article</dc:type>
<dc:date>200709</dc:date>
</metadata>
</record>
</ibecs-document>
